TScan Therapeutics Files Amendment to Annual Report

TL;DR

<b>TScan Therapeutics filed an amendment to its 2023 annual report, confirming its status as a non-seasoned issuer trading on Nasdaq.</b>

AI Summary

TScan Therapeutics, Inc. (TCRX) filed a Amended Annual Report (10-K/A) with the SEC on April 10, 2024. TScan Therapeutics, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2023. The company's common stock trades under the symbol TCRX on The Nasdaq Global Market. TScan Therapeutics is incorporated in Delaware and headquartered in Waltham, Massachusetts. The filing indicates the company is not a well-known seasoned issuer. The company has submitted all required reports for the preceding 12 months and the past 90 days.

Why It Matters

For investors and stakeholders tracking TScan Therapeutics, Inc., this filing contains several important signals. This amendment provides updated information for the fiscal year 2023, crucial for investors tracking the company's financial and operational status. The filing confirms TScan Therapeutics' compliance with SEC reporting requirements, indicating a level of operational stability in its disclosure processes.

Risk Assessment

Risk Level: low — TScan Therapeutics, Inc. shows low risk based on this filing. The filing is an amendment to a 10-K, suggesting it's a procedural update rather than a material event, thus posing low risk.

Analyst Insight

Review the specific changes in the amendment to understand any updated disclosures or corrections made by TScan Therapeutics.

Key Numbers

• 2023-12-31 — Fiscal Year End (Reporting period)
• 001-40603 — SEC File Number (Commission File Number)
• 82-5282075 — IRS Number (Employer Identification No.)
• TCRX — Trading Symbol (Common Stock)

Key Players & Entities

• TScan Therapeutics, Inc. (company) — Registrant name
• TCRX (company) — Trading Symbol
• The Nasdaq Global Market, LLC (company) — Exchange
• Delaware (company) — State of Incorporation
• Waltham (company) — City
• 2023-12-31 (date) — Fiscal year end
• 2024-04-10 (date) — Filing Date

FAQ

Industry Context

TScan Therapeutics operates in the biotechnology sector, focusing on developing T-cell receptor (TCR) engineered T cell therapies for cancer.

Regulatory Implications

The company is subject to standard SEC reporting requirements for publicly traded companies, including annual and periodic filings.

What Investors Should Do

1. Review the specific amendments made in the 10-K/A filing.
2. Analyze TScan Therapeutics' business and financial disclosures for the fiscal year 2023.
3. Monitor future filings for updates on clinical trials and regulatory progress.

Key Dates

• 2024-04-10: Filing Date — Amendment to 2023 Annual Report (10-K/A)
• 2023-12-31: Fiscal Year End — Period covered by the annual report

Year-Over-Year Comparison

This is an amendment to the previously filed 10-K for the fiscal year ended December 31, 2023.

Key Financial Figures

• $0.0001 — which registered Voting Common Stock, $0.0001 par value per share TCRX The Nasdaq
• $1 billion — anada and was responsible for more than $1 billion in annual sales. Prior to joining Alexi

Filing Documents

• d818033d10ka.htm (10-K/A) — 337KB
• d818033dex313.htm (EX-31.3) — 4KB
• d818033dex314.htm (EX-31.4) — 4KB
• 0001193125-24-091386.txt (&nbsp;) — 607KB
• tcrx-20231231.xsd (EX-101.SCH) — 5KB
• tcrx-20231231_cal.xml (EX-101.CAL) — 1KB
• tcrx-20231231_def.xml (EX-101.DEF) — 18KB
• tcrx-20231231_lab.xml (EX-101.LAB) — 24KB
• tcrx-20231231_pre.xml (EX-101.PRE) — 19KB
• d818033d10ka_htm.xml (XML) — 10KB

Executive Compensation

Executive Compensation 7 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 16 Item 13. Certain Relationships and Related Transactions, and Director Independence 20 Item 14. Principal Accountant Fees and Services 22 PART IV Item 15. Exhibits and Financial Statement Schedules 23

Signatures

Signatures 24 PART III Item10. Directors, Executive Officers and Corporate Governance. Information About Our Directors The following table identifies our current directors and sets forth certain information regarding the members of our board of directors, including their ages as of April 1, 2024, and years of tenure on our board of directors. Name Positions and Offices Held with TScan Director Since Age Timothy Barberich Director 2019 76 Stephen Biggar, M.D., Ph.D. Director 2021 53 Gavin MacBeath, Ph.D. Director, Chief Executive Officer 2023 54 Katina Dorton, J.D., M.B.A. Director 2021 66 R. Keith Woods Director 2023 56 Gabriela Gruia, M.D. Director 2021 67 Barbara Klencke, M.D. Director 2023 66 The names and certain biographical information about our current directors, including each director's business experience, director position held, information regarding involvement in certain legal or administrative proceeding, if applicable, and the director's experiences, qualifications, attributes, or skills are set forth below. Timothy Barberich has served as a member of our board of directors since March 2019 and as the chair of our board of directors since March 2021. Mr. Barberich is a founder, former Chairman and Chief Executive Officer of Sepracor Inc. ("Sepracor"), a publicly traded, research-based, pharmaceutical company based in Marlborough, Massachusetts, currently called Sunovion Pharmaceuticals Inc., which was acquired by Dainippon Sumitomo Pharma Co., Ltd. in 2009. He co-founded Sepracor in 1984 and served as Chief Executive Officer from 1984 to May 2007 and as Chairman of the Board from 1990 to 2009. He currently serves on the board of directors of Gila Therapeutics, Inc. He also previously served on the boards of directors of Frequency Therapeutics, Inc., Versicor Inc. and Verastem, Inc., and of Neurovance Inc, Inotek Pharmaceuticals, Inc., HeartWare International, Inc., Tokai Pharmaceuticals, B

View Full Filing

View this 10-K/A filing on SEC EDGAR